{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:42:10Z","timestamp":1792575730604,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01850-y","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:41:23Z","timestamp":1792568483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Toxicity Across the Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Joshua","family":"Lushington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salina","family":"Lalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shania","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Kandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Northend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky Dylan","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1850_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"1850_CR2","unstructured":"Tocchetti CG, Farmakis D, Koop Y et al. Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024(10):2055\u20132076"},{"issue":"1 28","key":"1850_CR3","first-page":"1","volume":"28","author":"FYN Ilessomo","year":"2023","unstructured":"Ilessomo FYN, Mandizadza OO, Mukuka C, Wang ZQ. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res 2023. 2023;28(1 28):1\u201314.","journal-title":"Eur J Med Res 2023"},{"issue":"12","key":"1850_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","volume":"26","author":"A Guha","year":"2020","unstructured":"Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, de Lima M, Al-Kindi S, Oliveira GH. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. Biol Blood Marrow Transpl. 2020;26(12):2211\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1850_CR5","doi-asserted-by":"publisher","first-page":"119147","DOI":"10.1016\/j.atherosclerosis.2025.119147","volume":"403","author":"R Gray","year":"2025","unstructured":"Gray R, Manisty C, Cheng R, Dastidar A, Mamas M, Ghosh A. Immune checkpoint inhibitors: Unravelling atherosclerotic cardiovascular risk. Atherosclerosis. 2025;403:119147.","journal-title":"Atherosclerosis"},{"key":"1850_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, Niimura T, Okada N, et al. Factors Associated With Immune Checkpoint Inhibitor\u2013Related Myocarditis. JAMA Oncol. 2019;5:1635.","journal-title":"JAMA Oncol"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-01002-w","volume":"23","author":"F Pirozzi","year":"2021","unstructured":"Pirozzi F, Poto R, Aran L, et al. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Curr Oncol Rep. 2021;23:1\u20138.","journal-title":"Curr Oncol Rep"},{"key":"1850_CR8","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, et al. Incidence of Cardiovascular Events in Patients Treated with Immune Checkpoint Inhibitors. J Clin Oncol. 2022;40:3430\u20138.","journal-title":"J Clin Oncol"},{"key":"1850_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, et al. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021;3:35.","journal-title":"JACC CardioOncol"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23:e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1850_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40959-022-00147-w","volume":"8","author":"MS Andres","year":"2022","unstructured":"Andres MS, Ramalingam S, Rosen SD, et al. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardio-oncology. 2022;8:21.","journal-title":"Cardio-oncology"},{"key":"1850_CR13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23:1739\u201347.","journal-title":"Eur J Heart Fail"},{"key":"1850_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","volume":"46","author":"E Raschi","year":"2023","unstructured":"Raschi E, Rossi S, De Giglio A, et al. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Saf. 2023;46:819\u201333.","journal-title":"Drug Saf"},{"key":"1850_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1850_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140:80.","journal-title":"Circulation"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, et al. Immune Checkpoint Inhibitor\u2013Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist. 2021;26:1052.","journal-title":"Oncologist"},{"issue":"13","key":"1850_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cancers17132063","volume":"17","author":"M Furlepa","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS. Management of Triple M Syndrome: A Narrative Review of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis, Myositis and Myocarditis. Cancers (Basel). 2025;17(13):2063.","journal-title":"Cancers (Basel)"},{"key":"1850_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","volume":"119","author":"DY Chen","year":"2020","unstructured":"Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119:1461\u201375.","journal-title":"J Formos Med Assoc"},{"key":"1850_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1078155216635853","volume":"23","author":"CA Dasanu","year":"2017","unstructured":"Dasanu CA, Jen T, Skulski R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract. 2017;23:231\u20134.","journal-title":"J Oncol Pharm Pract"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/jitc-2019-000261","volume":"8","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8:e000261.","journal-title":"J Immunother Cancer"},{"key":"1850_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacbts.2023.12.007","volume":"9","author":"K Nitz","year":"2024","unstructured":"Nitz K, Herrmann J, Lerman A, Lutgens E. Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic Targets in Atherosclerosis? JACC Basic Transl Sci. 2024;9:827\u201343.","journal-title":"JACC Basic Transl Sci"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42:4964\u201377.","journal-title":"Eur Heart J"},{"key":"1850_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","volume":"4","author":"GA Suero-Abreu","year":"2022","unstructured":"Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4:598\u2013615.","journal-title":"JACC CardioOncol"},{"key":"1850_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"1850_CR26","doi-asserted-by":"crossref","unstructured":"De Perna ML, Rigamonti E, Zannoni R, et al. Immune Checkpoint Inhibitors and Cardiovascular Adverse Events. ESC Heart Fail; 2025.","DOI":"10.1002\/ehf2.15281"},{"key":"1850_CR27","first-page":"101278","volume":"49","author":"S Talukder","year":"2023","unstructured":"Talukder S, Ghose A, Chakraborty T, Olsson-Brown A, Ramalingam S, Rosen SD, Young K, Lyon AR, Ghosh AK. Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients. Int J Cardiol Heart Vasc. 2023;49:101278.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1850_CR28","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72:3158\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"1850_CR29","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41:1733\u201343.","journal-title":"Eur Heart J"},{"issue":"1","key":"1850_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40959-025-00393-8","volume":"11","author":"A Ghose","year":"2025","unstructured":"Ghose A, Kandala A, Sabnis I, Hasanova M, Simela C, Manisty C, Banerjee S, Szmit S, Westwood M, Macedo AVS, Martinez DS, Daniele AJ, Noronha V, Singh T, Ky B, Adeleke S, Maniam A, Casselli SJ, Lenihan DJ, Dent S, Ghosh AK. A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries. Cardio-oncology (London England). 2025;11(1):97. https:\/\/doi.org\/10.1186\/s40959-025-00393-8.","journal-title":"Cardio-oncology (London England)"},{"key":"1850_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021;77:1503\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375:1749.","journal-title":"N Engl J Med"},{"key":"1850_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/ehjci\/jeab128","volume":"23","author":"S Rosmini","year":"2022","unstructured":"Rosmini S, Seraphim A, Knott K, et al. Non-invasive characterization of pleural and pericardial effusions using T1 mapping by magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2022;23:1117\u201326.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1850_CR34","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020;141:2031\u20134.","journal-title":"Circulation"},{"key":"1850_CR35","first-page":"800","volume":"6","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Siddiqui BA, Deswal A. Steroids in Immune Checkpoint Inhibitor Myocarditis. Cardio Oncol. 2024;6:800\u20133.","journal-title":"Cardio Oncol"},{"key":"1850_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","volume":"4","author":"J Moslehi","year":"2022","unstructured":"Moslehi J, Salem JE. Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions. JACC CardioOncol. 2022;4:704\u20137.","journal-title":"JACC CardioOncol"},{"key":"1850_CR37","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/jitc-2020-001887","volume":"8","author":"J Cautela","year":"2020","unstructured":"Cautela J, Zeriouh S, Gaubert M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8:1887.","journal-title":"J Immunother Cancer"},{"key":"1850_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines\u00ae Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024;22:582\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"1850_CR39","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1850_CR40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10(10):1390\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3065.","journal-title":"JAMA Oncol"},{"key":"1850_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al. Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov. 2023;13:1100\u201315.","journal-title":"Cancer Discov"},{"key":"1850_CR42","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s12012-024-09918-6","volume":"24","author":"S Tan","year":"2024","unstructured":"Tan S, Qi C, Zeng H, et al. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review. Cardiovasc Toxicol. 2024;24:1174.","journal-title":"Cardiovasc Toxicol"},{"key":"1850_CR43","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","volume":"70","author":"A Inno","year":"2021","unstructured":"Inno A, Maurea N, Metro G, et al. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunol Immunother. 2021;70:3041\u201353.","journal-title":"Cancer Immunol Immunother"},{"key":"1850_CR44","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358.","journal-title":"Lancet Oncol"},{"key":"1850_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","volume":"19","author":"CE Brown","year":"2019","unstructured":"Brown CE, Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 2019;19:73\u20134.","journal-title":"Nat Rev Immunol"},{"key":"1850_CR46","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","volume":"131","author":"AI Salter","year":"2018","unstructured":"Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor\u2013modified T cells: CD19 and the road beyond. Blood. 2018;131:2621.","journal-title":"Blood"},{"key":"1850_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000496870","volume":"46","author":"M Subklewe","year":"2019","unstructured":"Subklewe M, von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother. 2019;46:15\u201324.","journal-title":"Transfus Med Hemother"},{"key":"1850_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12170-020-00661-5","volume":"15","author":"DH Chen","year":"2021","unstructured":"Chen DH, Tyebally S, Mallouppas M, et al. CAR T Cell and BiTE Therapy\u2014New Therapies, New Risks? Curr Cardiovasc Risk Rep. 2021;15:1. https:\/\/doi.org\/10.1007\/s12170-020-00661-5.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"10","key":"1850_CR49","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, V\u00f6lkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, R\u00f6sler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Kr\u00f6nke G, Schett G. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"1","key":"1850_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1850_CR51","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Mu\u00f1oz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All. ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"1850_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1850_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"1850_CR54","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"10299","key":"1850_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O\u2019Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"issue":"10297","key":"1850_CR56","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O\u2019Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"4","key":"1850_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fern\u00e1ndez de Larrea C, Mart\u00ednez-L\u00f3pez J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"8","key":"1850_CR58","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"1850_CR59","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"10254","key":"1850_CR60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"14","key":"1850_CR61","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood"},{"issue":"6","key":"1850_CR62","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jha2.1020","volume":"5","author":"DH Chen","year":"2024","unstructured":"Chen DH, O\u2019Reilly M, Cheok KP, Low R, Puranik R, Clark S, Walker JM, Manisty C, Ghosh AK, Roddie C. CD19-targeting chimeric antigen receptor T-cell therapy is safe and effective for intra-cardiac B cell non-Hodgkin lymphoma. EJHaem. 2024;5(6):1283\u20139.","journal-title":"EJHaem"},{"issue":"2","key":"1850_CR63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"21","key":"1850_CR64","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, L\u00f3pez JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"issue":"1","key":"1850_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1850_CR66","first-page":"52","volume":"10","author":"S Maleki","year":"2024","unstructured":"Maleki S, Esmaeili Z, Seighali N, Shafiee A, Namin SM, Zavareh MAT, Khamene SS, Mohammadkhawajah I, Nanna M, Alizadeh-Asl A, Kwan M, Hosseini J. Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardiooncology. 2024;10(1):52.","journal-title":"Cardiooncology"},{"issue":"1","key":"1850_CR67","first-page":"18","volume":"9","author":"DH Lee","year":"2023","unstructured":"Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023;9(1):18.","journal-title":"Cardiooncology"},{"issue":"1","key":"1850_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2(1):97\u2013109.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"1850_CR69","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","volume":"5","author":"B Lefebvre","year":"2023","unstructured":"Lefebvre B, Kang Y, Vakilpour A, Onoue T, Frey NV, Brahmbhatt P, Huang B, Oladuja K, Koropeckyj-Cox D, Wiredu C, Smith AM, Chittams J, Carver J, Scherrer-Crosbie M. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. JACC CardioOncol. 2023;5(6):747\u201354.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"1850_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","volume":"27","author":"T Joseph","year":"2025","unstructured":"Joseph T, Sanchez J, Abbasi A, Zhang L, Sica RA, Duong TQ. Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review. Curr Oncol Rep. 2025;27(2):135\u201347.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1850_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1850_CR72","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.jaccas.2022.09.004","volume":"8","author":"DH Lee","year":"2022","unstructured":"Lee DH, Jain M, Lazaryan A, Locke FL, Jeong D, Alomar M. Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma. JACC Case Rep. 2022;8:101634.","journal-title":"JACC Case Rep"},{"issue":"18","key":"1850_CR73","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, Steingart RM, Mahmood SS, Schaffer WL, Perales MA, Shouval R. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021;78(18):1800\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1850_CR74","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, Harchandani B, Perales MA, Geyer MB, Park JH, Palomba ML, Shouval R, Tomas AA, Shah GL, Yang EH, Gaut DL, Rothberg MV, Horn EM, Leonard JP, Van Besien K, Frigault MJ, Chen Z, Mehrotra B, Neilan TG, Steingart RM. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44(22):2029\u201342.","journal-title":"Eur Heart J"},{"issue":"25","key":"1850_CR75","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1850_CR76","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, Spendley L, Nikiforow S, Jacobson C, Nohria A. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation. 2020;142(17):1687\u201390.","journal-title":"Circulation"},{"key":"1850_CR77","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, ScherrerCrosbie M. Cardiovascular Efects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol. 2020;2:193\u2013203.","journal-title":"JACC CardioOncol"},{"issue":"7","key":"1850_CR78","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","volume":"107","author":"RE Steiner","year":"2022","unstructured":"Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022;107(7):1555\u201366.","journal-title":"Haematologica"},{"issue":"3","key":"1850_CR79","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bjh.19497","volume":"205","author":"R Shouval","year":"2024","unstructured":"Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, Raj SS, Giralt SA, Palomba ML, Dahi PB, Walji M, Salles G, Nath K, Geyer MB, Park JH, Fein JA, Kosmidou I, Shah GL, Liu JE, Perales MA, Mahmood SS. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Br J Haematol. 2024;205(3):978\u201389.","journal-title":"Br J Haematol"},{"issue":"8","key":"1850_CR80","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","volume":"24","author":"DS Burstein","year":"2018","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transpl. 2018;24(8):1590\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"1850_CR81","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017;45(2):e124\u201331.","journal-title":"Crit Care Med"},{"key":"1850_CR82","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","volume":"69","author":"F Korell","year":"2024","unstructured":"Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, M\u00fcller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 2024;69:102504.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"1850_CR83","doi-asserted-by":"publisher","first-page":"e002303","DOI":"10.1136\/jitc-2020-002303","volume":"9","author":"JE Brammer","year":"2021","unstructured":"Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer. 2021;9(8):e002303.","journal-title":"J Immunother Cancer"},{"issue":"20","key":"1850_CR84","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928\u201340.","journal-title":"Eur Heart J"},{"issue":"1","key":"1850_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1850_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"key":"1850_CR87","doi-asserted-by":"publisher","unstructured":"Ayoub C, Appari L, Pereyra M, Farina JM, Chao CJ, Scalia IG, Mahmoud AK, Abbas MT, Baba NA, Jeong J, Lester SJ, Patel BN, Arsanjani R, Banerjee I. Multimodal Fusion Artificial Intelligence Model to Predict Risk for MACE and Myocarditis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy. JACC Adv. 2024 Dec 13;4(1):101435. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101435","DOI":"10.1016\/j.jacadv.2024.101435"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01850-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:02:31Z","timestamp":1792573351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01850-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"17 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}